Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
F 28.33 1.25% 0.35
BLUE closed up 1.25 percent on Tuesday, April 13, 2021, on 38 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BLUE trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal 1.25%
Stochastic Reached Oversold Weakness 1.25%
Down 3 Days in a Row Weakness 1.25%
Down 4 Days in a Row Weakness 1.25%
Down 5 Days in a Row Weakness 1.25%
Lower Bollinger Band Touch Weakness 1.25%
Oversold Stochastic Weakness 1.25%
Narrow Range Bar Range Contraction 0.60%
Older End-of-Day Signals for BLUE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 16 hours ago
60 Minute Opening Range Breakout about 16 hours ago
Up 1% about 16 hours ago
Lower Bollinger Band Support about 19 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

bluebird bio, Inc. Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Summit Childhood Human Disease Human Diseases Sickle Cell Disease Genetic Genealogy Thalassemia Iglo Blood Disorder Leukodystrophy Oncology Diseases

Is BLUE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Apr 13 BLUE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021
Apr 13 CLASS ACTION UPDATE for BLUE, KDMN and EBON: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Apr 13 DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 13 Final Deadline Today: Rosen, National Trial Counsel, Encourages bluebird bio, Inc. Investors with Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE
Apr 13 SHAREHOLDER ALERT: BLUE VLDR RIDE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Apr 13 BLUE Final Deadline Today: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021
Apr 13 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, OTRK and GOEV
Apr 13 FINAL DEADLINE APRIL 13: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 12 DEADLINE TUESDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 12 BLUE INVESTOR FILING DEADLINE TOMORROW : Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.
See more BLUE news...

Indicators

Indicator Value
52 Week High 72.5
52 Week Low 24.24
Average Volume 2,479,091
200-Day Moving Average 48.60
50-Day Moving Average 32.92
20-Day Moving Average 29.89
10-Day Moving Average 29.34
Average True Range 1.68
ADX 18.08
+DI 20.04
-DI 33.42
Chandelier Exit (Long, 3 ATRs ) 28.61
Chandelier Exit (Short, 3 ATRs ) 32.23
Upper Bollinger Band 32.32
Lower Bollinger Band 27.47
Percent B (%b) 0.18
BandWidth 16.22
MACD Line -1.12
MACD Signal Line -1.16
MACD Histogram 0.037
Fundamentals Value
Market Cap 1.88 Billion
Num Shares 66.2 Million
EPS -12.00
Price-to-Earnings (P/E) Ratio -2.36
Price-to-Sales 10.47
Price-to-Book 1.92
PEG Ratio 0.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.97
Resistance 3 (R3) 29.80 29.08 29.70
Resistance 2 (R2) 29.08 28.66 29.17 29.61
Resistance 1 (R1) 28.71 28.40 28.89 28.88 29.52
Pivot Point 27.99 27.99 28.08 28.07 27.99
Support 1 (S1) 27.61 27.57 27.80 27.78 27.14
Support 2 (S2) 26.89 27.31 26.98 27.05
Support 3 (S3) 26.52 26.89 26.96
Support 4 (S4) 26.69